Scripps Florida Opens its Screening Technology to Florida Scientists
News Jan 23, 2006
Officials at Scripps Florida have announced the launch of the biomedical research institute's "Access to Technologies" program, which invites scientists from Florida universities and other academic research institutions to use screening technologies at Scripps Florida's facilities in Jupiter for qualifying projects.
Access to Scripps Florida's High Throughput Screening operation, similar to that used widely by the pharmaceutical industry, should speed up the process of discovering drugs to treat a variety of human illnesses.
"Inviting our state's outstanding scientists to share in the extraordinary technologies available at Scripps Florida is another example of how our investment in biomedical research is contributing to the biomedical knowledge base here," said Florida Governor Jeb Bush.
"This program will pay off academically, economically, and ultimately lead to better health for Floridians and people everywhere."
"Science is always advanced through sharing," said Richard A. Lerner, president of the Scripps Florida's parent institution, The Scripps Research Institute in La Jolla, California.
"I'm convinced that sharing our technologies with researchers throughout Florida will quicken the pace of progress, further challenging both them and us to find answers to difficult health questions."
Key components of the HTS process include the institute's screening system, purchased for Scripps Florida from Kalypsys of La Jolla, California.
These automated robots are designed to determine and analyze the biological or biochemical activity of a large number of drug-like compounds, useful in discovering pharmacological targets or pharmacologically profiling a cellular or biochemical pathway of promise.
Typically, HTS assays are performed in sets of either 96 or 384 samples on each automation-friendly plate.
The Scripps Florida technology can use plates that can hold up to 1,536 samples at a time, quickening the pace of analysis and discovery. The robots are two of only a handful of such machines in nonprofit research institutions.
The facility also has several other robots that help scientists develop experiments suitable for the Kalypsys system.
Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT BiotechNews
Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.READ MORE
XenoGesis and BioAscent Forge Alliance to Offer Enhanced Integrated Drug Discovery ServicesNews
XenoGesis and BioAscent Discovery Limited have announced a collaboration to offer an enhanced range of integrated drug discovery services, including medicinal chemistry, biology and DMPK.READ MORE
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE